From GlobeNewswire: 2024-05-30 07:00:00

Roivant (Nasdaq: ROIV) reported financial results for Q4 and FY 2024, with $75.1M in VTAMA net product revenue. Brepocitinib showed promising results in non-infectious uveitis, supporting a pivotal program in second half of 2024. Immunovant to initiate 4-5 potentially registrational studies with IMVT-1402 by March 2025. FDA accepted VTAMA sNDA for atopic dermatitis, with PDUFA action expected in Q4 2024. Roivant completed a share repurchase of Sumitomo’s stake for $648M.

Priovant announced positive results for brepocitinib in non-infectious uveitis, with the best Treatment Failure rates observed. Immunovant plans to initiate 4-5 registrational studies with IMVT-1402 by March 2025. Dermavant reported VTAMA net product revenue of $75.1M for FY 2024. Roivant renegotiated Dermavant’s debt obligations, reducing potential cash payments by $300M. Roivant has $852M in share repurchase authorization.

Roivant had consolidated cash of $6.6B at March 31, 2024. The board approved a $1.5B share repurchase program, completing a $648M repurchase of Sumitomo’s stake. Major upcoming milestones include PDUFA action for VTAMA in atopic dermatitis in Q4 2024, topline data from namilumab trial in Q4 2024, and topline data from brepocitinib trial in DM in 2025. Immunovant plans to initiate studies in 10 indications by March 31, 2026 for IMVT-1402.



Read more at GlobeNewswire:: Roivant Reports Financial Results for the Fourth Quarter